Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple sclerosis

Aún no traducido Aún no traducido
Categoría Estudio primario
Revista28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Published in: Abstract meeting of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012, Lyon, France. Multiple Sclerosis
Año 2012
Este artículo no tiene resumen
Epistemonikos ID: 0fb03232f15d461bb7a85436534c502a04189ad1
First added on: Oct 30, 2021